April 9, 2015
Merck KGaA and Pfizer Inc. have said that they have entered into an agreement to copromote Pfizer’s non-small cell lung cancer treatment Xalkori (crizotinib), an anaplastic lymphoma kinase (ALK) inhibitor. The agreement covers the US, Canada, Japan, and five European...read more